European equities traded in the US as American depositary receipts started the week off higher late Monday morning, rising 0.32% to 1,343.34 on the S&P Europe Select ADR Index.
From continental Europe, the gainers were led by biopharmaceutical companies argenx (ARGX) and Grifols (GRFS), which rose 4.3% and 3.9% respectively. They were followed by medical device maker EDAP TMS (EDAP) and pharmaceutical company Ascendis Pharma (ASND), which increased 3.1% and 2.7% respectively.
The decliners from continental Europe were led by biotech firm Evaxion Biotech (EVAX) and biopharmaceutical company DBV Technologies (DBVT), which fell 18% and 3.1% respectively. They were followed by biopharmaceutical company Cellectis (CLLS) and petroleum refiner Equinor (EQNR), which were down 2.8% and 2.4% respectively.
From the UK and Ireland, the gainers were led by biopharmaceutical company Bicycle Therapeutics (BCYC) and biotech firm Autolus Therapeutics (AUTL), which advanced 8.6% and 5% respectively. They were followed by biopharmaceutical companies Verona Pharma (VRNA) and Amarin (AMRN), which were up 4.6% and 2.4% respectively.
The decliners from the UK and Ireland were led by biopharmaceutical company Mereo BioPharma Group (MREO) and biotech firm Trinity Biotech (TRIB), which dropped 3.7% and 2.2% respectively. They were followed by oil and gas company BP (BP) and insurance company Prudential (PUK), which lost 2.1% and 1.1% respectively.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。